Research programme: factor IX therapeutic - MDRNA

Drug Profile

Research programme: factor IX therapeutic - MDRNA

Latest Information Update: 25 Aug 2010

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Nastech Pharmaceutical Company
  • Developer Marina Biotech
  • Class Blood coagulation factors
  • Mechanism of Action Factor IX stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Haemophilia

Most Recent Events

  • 25 Aug 2010 Discontinued for Haemophilia in USA (Parenteral)
  • 01 Apr 2010 MDRNA acquires Cequent Pharmaceuticals and is renamed Marina Biotech
  • 17 Apr 2008 Early research in Haemophilia in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top